Mineralys Therapeutics, Inc.
No enriched coverage for $MLYS in the last 7 days.
Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares on July 13, 2026, per an SEC Form 4. The sale used a weighted average price of $27.24, with shares closing at $27.59. Afterward, he held 603,621 shares. The trade followed a Rule 10b5-1 plan from January 2025. Mineralys is developing lorundrostat for uncontrolled hypertension.
Mineralys Therapeutics, a clinical-stage biopharma, is preparing for a Dec. 22 FDA decision on lorundrostat for resistant hypertension. The article says an insider at Mineralys (Rodman) exercised options struck as low as $1.08 and sold at $27.28 for a $557,000 gain. It also notes the company raised about $150 million in June and expects funding into 2028.
Rodman David Malcom (Chief Medical Officer) sold 20,407 shares of Mineralys Therapeutics, Inc. (MLYS) at an average of $27.28 ($26.61–$27.58, $0.56M total) across 2 trades over 2026-07-13 to 2026-07-15 under a Rule 10b5-1 trading plan.
Recent MLYS coverage spans financial news, insider activity and mergers & acquisitions.
In the last 30 days, MLYS insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($1.1M). The most active reporter was Rodman David Malcom, Chief Medical Officer, with 4 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The insider sale is a modest portfolio adjustment, not a fundamental change, but it can add short-term sentiment noise ahead of the December FDA date referenced in the headline.
Insider option monetization is unlikely to change the fundamental FDA catalyst, but it can add near-term sentiment noise into the decision window.
This is an insider sale disclosure, not a new operating or financial catalyst.
The financing and rights expansion can de-risk commercialization funding for lorundrostat, but the staged debt increases leverage and may constrain flexibility.
The offering and planned royalty repurchase are concrete capital-structure and cash-use events that can shift dilution expectations and near-term funding risk.
alphai scores every news story that mentions MLYS with an AI model for sentiment and relevance, and aggregates insider trades from Mineralys Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mineralys Therapeutics CEO Jon Congleton sold 10,700 shares on July 13, 2026, per an SEC Form 4. The sale used a weighted average price of $27.24, with shares closing at $27.59. Afterward, he held 603,621 shares. The trade followed a Rule 10b5-1 plan from January 2025. Mineralys is developing lorundrostat for uncontrolled hypertension.
4 min readMineralys Therapeutics, a clinical-stage biopharma, is preparing for a Dec. 22 FDA decision on lorundrostat for resistant hypertension. The article says an insider at Mineralys (Rodman) exercised options struck as low as $1.08 and sold at $27.28 for a $557,000 gain. It also notes the company raised about $150 million in June and expects funding into 2028.
5 min readRodman David Malcom (Chief Medical Officer) sold 20,407 shares of Mineralys Therapeutics, Inc. (MLYS) at an average of $27.28 ($26.61–$27.58, $0.56M total) across 2 trades over 2026-07-13 to 2026-07-15 under a Rule 10b5-1 trading plan.
1 min readMineralys Therapeutics (MLYS) revised its deal with Tanabe Pharma to obtain full worldwide rights to lorundrostat without future royalties. MLYS will pay $200M upfront and up to $365M based on commercial targets, and secured a staged loan up to $500M from Pharmakon Advisors tied to FDA approval and sales milestones. Goldman Sachs reiterated Buy and set a $42 target.
4 min readMineralys Therapeutics (MLYS) presented ENDO 2026 late-breaking data (TheFly, June 14) from post hoc analyses of Launch-HTN and Advance-HTN trials on lorundrostat’s effects on heart-failure biomarkers, including increased renin, reduced angiotensinogen, and lower NT-proBNP. MLYS also priced an underwritten public offering of 5.66M shares at $26.50, raising ~$150M gross, to fund part of a $200M royalty repurchase from Tanabe Pharma.
4 min readCongleton Jon (Chief Executive Officer) sold 75,000 shares of Mineralys Therapeutics, Inc. (MLYS) at an average of $26.14 ($25.94–$26.82, $1.96M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.
2 min readWarren Eric (Chief Commercial Officer) sold 104,124 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.90 ($2.70M total) on 2026-06-26 under a Rule 10b5-1 trading plan.
2 min readMineralys Therapeutics (NASDAQ: MLYS) said it will repurchase all future royalty payments to Tanabe Pharma for lorundrostat under their license agreement for $200 million upfront and up to $100 million tied to commercial milestones. The company also entered a $500 million senior secured term loan with Pharmakon Advisors, with $100 million funded at closing, and priced an underwritten ~$150 million common stock offering.
4 min readVelan Capital sold 140,000 shares of Mineralys Therapeutics (MLYS), worth about $4.1 million, according to the report. Mineralys’ drug lorundrostat, an aldosterone synthase inhibitor for hypertension, is under FDA review for its first combination therapy application, with a decision expected by Dec. 22, 2026. Mineralys reported a $39.3 million Q1 loss and $646 million cash at March-end.
4 min readMineralys Therapeutics (Nasdaq: MLYS) announced it will present new Phase 3 data from its Launch-HTN trial for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The data, focusing on patients with uncontrolled hypertension and chronic kidney disease (CKD), will be presented orally on May 30, 2026, by Liffert Vogt, MD, PhD. The trial evaluated lorundrostat's efficacy and safety in adults whose blood pressure remained uncontrolled despite existing antihypertensive medications, with the primary endpoint being the change from baseline in systolic BP at six weeks.
4 min read
